10-Q: Neuphoria Therapeutics Reports Q2 2025 Results, Highlights Redomiciliation and Milestone Payment

Neuphoria Therapeutics reports its Q2 2025 results, marking its redomiciliation to the US and highlighting a significant milestone payment from Merck.

Summary

• Neuphoria Therapeutics Inc., a clinical-stage biotechnology company, has filed its Form 10-Q for the quarter ended December 31, 2024.
• The company completed its redomiciliation from Australia to Delaware on December 23, 2024, with shares of common stock commencing trading on Nasdaq on December 24, 2024, under the ticker symbol NEUP.
• The company reported revenue of $662,715 for both the three and six months ended December 31, 2024, due to a milestone payment from Carina Biotech.
• Research and development expenses were $1.7 million and $3.6 million for the three and six months ended December 31, 2024, respectively.
• General and administrative expenses were $2.6 million and $4.3 million for the three and six months ended December 31, 2024, respectively.
• The company reported a net loss of $1.9 million and $2.7 million for the three and six months ended December 31, 2024, respectively.
• As of December 31, 2024, the company had cash and cash equivalents of $4.3 million and an accumulated deficit of $180.7 million.
• The company believes its existing cash and cash equivalents will be sufficient to fund development activities into late in the fourth quarter of fiscal year 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within twelve months of the issuance date of these financial statements.
• The company is seeking additional funding through public offerings, private placements, debt financings, collaborations, or other strategic transactions.
• A $15 million milestone payment is expected from Merck & Co., Inc. following the initiation of a Phase 2 clinical trial for MK-1167.
• The company issued 128,368 shares of common stock under its ATM facility on February 12, 2025, for net proceeds of approximately $0.7 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has achieved certain milestones and is expecting a significant payment from Merck, it is also facing financial challenges and has substantial doubt about its ability to continue as a going concern. The need for additional funding and the potential for dilution are also negative factors.

Positives

• The company successfully completed its redomiciliation to the United States.
• The company received a milestone payment of $662,715 from Carina Biotech.
• The company anticipates a $15 million milestone payment from Merck & Co., Inc.
• General and administrative expenses decreased by $0.6 million during the six months ended December 31, 2024, compared to the same period in 2023.
• Research and development expenses decreased by approximately $0.3 million for the three months ended December 31, 2024, compared to the same period in 2023.

Negatives

• The company reported a net loss of $1.9 million and $2.7 million for the three and six months ended December 31, 2024, respectively.
• The company has an accumulated deficit of $180.7 million as of December 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern within twelve months of the issuance date of these financial statements.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company needs to raise additional capital to finance its future operations.
• Failure to obtain sufficient funding could force the company to delay, reduce, or eliminate some or all of its research and development programs or commercialization activities.
• The company's stock price has been volatile and could be subject to wide fluctuations.
• The company may never succeed in achieving regulatory approval for any of its product candidates.

Future Outlook

The company believes its existing cash and cash equivalents, combined with its existing ATM facility, will be sufficient to continue funding its development activities into late in the fourth quarter of fiscal year 2025. The company expects to receive a $15 million milestone payment from Merck & Co., Inc. The company expects that, together with this milestone payment, the cash on hand and its ATM facility, it will likely have sufficient funds into the fourth fiscal quarter of 2026, assuming no material changes to projected costs, expansion, or timing of its clinical trials.

Management Comments

• Management believes the pro rata allocation results in a reasonable estimate of the headcount costs associated with each of the programs noted above.

Industry Context

Neuphoria Therapeutics operates in the competitive biopharmaceutical industry, focusing on neuropsychiatric disorders. The company's lead product candidate, BNC210, targets social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD), areas with significant unmet medical needs. The company also has a strategic partnership with Merck & Co., Inc. to develop treatments for cognitive deficits in Alzheimer's disease and other central nervous system conditions.

Comparison to Industry Standards

• It is difficult to compare Neuphoria's results directly to industry standards without knowing the specific details of its clinical trials and development programs.
• However, the company's focus on neuropsychiatric disorders and its partnership with Merck & Co., Inc. are consistent with industry trends.
• Many biotechnology companies in the early stages of development experience net losses and rely on external funding to support their operations.
• The company's cash runway into late in the fourth quarter of fiscal year 2025 is relatively short, which is a common challenge for biotechnology companies.
• The expected $15 million milestone payment from Merck & Co., Inc. is a positive development that could extend the company's cash runway.

Related Party Transactions

• In December 2023, we entered into an engagement letter with WG Partners LLP to provide financial advisory services to Bionomics, our predecessor entity.
• David Wilson, a director of Neuphoria, is the Chairman and Chief Executive Officer of WG Partners.
• During the three and six months ended December 31, 2024 , we paid WG Partners $ 59,841 and $ 79,206 , respectively, for its services under terms and conditions that are on an arms-length basis.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected if the company is forced to delay, reduce, or eliminate some or all of its research and development programs or commercialization activities.
• Customers (patients) may benefit from the successful development and commercialization of the company's product candidates.
• Suppliers and creditors may be affected if the company is unable to meet its financial obligations.

Next Steps

• Continue clinical development of BNC210 and other product candidates.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Raise additional capital through public offerings, private placements, debt financings, collaborations, or other strategic transactions.
• Advance preclinical assets targeting Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Key Dates